SCHEMBL5553322

SCHEMBL5553322

O=C(c1cc(C(F)(F)F)cc(C(F)(F)F)c1)N1CCC2(CC1)C(=O)NCN2Cc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP2 O75604 12/20 0.63
CYP3A4 P08684 8/20 0.58
OPRD1 P41143 1/20 0.55
TACR1 P25103 1/20 0.55
SMN1; SMN2 Q16637 7/20 0.53
TSHR P16473 5/20 0.53
CYP2C9 P11712 4/20 0.53
ALDH1A1 P00352 2/20 0.53
CYP2C19 P33261 3/20 0.52
CYP1A2 P05177 2/20 0.52
CYP2D6 P10635 4/20 0.52
HSD17B10 Q99714 2/20 0.52
SLC6A9 P48067 1/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 1/20 0.48
MAPK1 P28482 1/20 0.48
HIF1A Q16665 1/20 0.48
SIGMAR1 Q99720 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5557537 0.89 USP2 (0.52) USP2CYP3A4OPRD1TACR1SMN1; SMN2
SCHEMBL5557693 0.82 CYP3A4 (0.55) USP2CYP3A4OPRD1TACR1SMN1; SMN2
SCHEMBL5553371 0.82 CYP3A4 (0.61) USP2CYP3A4OPRD1SMN1; SMN2TSHR
SCHEMBL5553342 0.81 USP2 (0.62) USP2CYP3A4OPRD1TACR1SMN1; SMN2
SCHEMBL5558262 0.79 USP2 (0.49) USP2CYP3A4SMN1; SMN2TSHRCYP2C9
SCHEMBL5559624 0.78 CYP3A4 (0.51) USP2CYP3A4OPRD1TACR1SMN1; SMN2
SCHEMBL5557913 0.77 PLD2 (0.55) USP2CYP3A4OPRD1TSHRCYP2C19
SCHEMBL5557707 0.77 USP2 (0.53) USP2CYP3A4OPRD1SMN1; SMN2TSHR
SCHEMBL5557778 0.77 CYP3A4 (0.49) USP2CYP3A4TACR1SMN1; SMN2TSHR
SCHEMBL5553206 0.77 RHOC (0.52) USP2CYP3A4OPRD1TACR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6482829-B2 CENTRAL NERVOUS SYSTEM DISORDERS; HEEADACHES, ANTIINFLAMMATORY AGENTS HOFFMANN-LA ROCHE INC. 2002-11-19 US claimed
US-20020006932-A1 Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor F. HOFFMANN-LA ROCHE AG (CH) 2002-01-17 US claimed
EP-1292596-B1 1,3,8-TRIAZA-SPIRO¬4,5 DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2007-12-19 EP disclosed
EP-1292596-A1 1,3,8-TRIAZA-SPIRO[4,5]DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-03-19 EP disclosed
US-6482829-B2 CENTRAL NERVOUS SYSTEM DISORDERS; HEEADACHES, ANTIINFLAMMATORY AGENTS HOFFMANN-LA ROCHE INC. 2002-11-19 US disclosed
US-20020006932-A1 Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor F. HOFFMANN-LA ROCHE AG (CH) 2002-01-17 US disclosed
WO-2001094346-A1 1,3,8-TRIAZA-SPIRO'4,5!DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006932-A1 Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor TACR1, TACR2, NPR1 USP2 3849/4885CYP3A4 3223/4885OPRD1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.